|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
|
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Property, plant and equipment | ||||||||
| Right-of-use assets | ||||||||
| Goodwill | ||||||||
| Other intangible assets | ||||||||
| Investments accounted for using the equity method | ||||||||
| Other non-current assets | ||||||||
| Non-current income tax assets | ||||||||
| Deferred tax assets | ||||||||
| Non-current assets | ||||||||
| Inventories | ||||||||
| Accounts receivable | ||||||||
| Other current assets | ||||||||
| Current income tax assets | ||||||||
| Cash and cash equivalents | ||||||||
| Current assets | ||||||||
| Non-current assets or disposal groups classified as held for sale | ||||||||
| Total assets | ||||||||
| Equity and liabilities | ||||||||
| Equity attributable to equity holders of Sanofi | ||||||||
| Equity attributable to non-controlling interests | ||||||||
| Total equity | ||||||||
| Long-term debt | ||||||||
| Non-current lease liabilities | ||||||||
| Non-current liabilities related to business combinations and to non-controlling interests | ||||||||
| Non-current provisions and other non-current liabilities | ||||||||
| Non-current income tax liabilities | ||||||||
| Deferred tax liabilities | ||||||||
| Non-current liabilities | ||||||||
| Accounts payable | ||||||||
| Current liabilities related to business combinations and to non-controlling interests | ||||||||
| Current provisions and other current liabilities | ||||||||
| Current income tax liabilities | ||||||||
| Current lease liabilities | ||||||||
| Short-term debt and current portion of long-term debt | ||||||||
| Current liabilities | ||||||||
| Liabilities included in disposal groups classified as held for sale | ||||||||
| Total equity and liabilities |
Loading...
